

Peripartum cardiomyopathy and thrombotic complications

 Ugur Aksu,¹  Selim Topcu,²  Oktay Gulcu,¹  Ibrahim Halil Tanboga²

¹Department of Cardiology, Erzurum Training and Research Hospital, Erzurum, Turkey

²Department of Pathology, Ataturk University Faculty of Medicine, Erzurum, Turkey

Cite this article as: Aksu U, Topcu S, Gulcu O, Tanboga IH. Peripartum cardiomyopathy and thrombotic complications. *North Clin Istanbul* 2019;6(1):102.

We would like to thank Biteker et al. [1] for their interest and positive and constructive comments regarding our case [2]. Peripartum cardiomyopathy (PPCMP) is a life-threatening clinical condition in which thromboembolic complications are frequent. Both the prothrombotic status of pregnancy and stasis as a result of heart failure may lead to thromboembolic complications [3]. The incidence of PPCMP and cardiac thrombus in literature is very variable. In one study, the incidence was reported to be 17%, while another study indicated 30% [4, 5]. It has even been reported in previous studies that up to 53% of cases of PPCMP have thromboembolism [6, 7]. In conclusion, the exact incidence of these patients is not known since they are both rare and could be diagnosed as a result of thromboembolic complications such as pulmonary embolism or ischemic stroke [8].

The decision of anticoagulant therapy in PPCMP patients is still controversial, and the patient's compliance, the degree of heart failure, and other clinical conditions should be taken into account when deciding on anticoagulant therapy [8].

REFERENCES

1. Biteker M, Çil C, Çelik O, Gökçek A, Kayataş K. The Therapeutic Dilemma of Peripartum Cardiomyopathy. *North Clin Istanbul* 2019;6:100–1.
2. Aksu U, Topcu S, Gulcu O, Tanboga IH. Peripartum cardiomyopathy and ventricular thrombus: A case report and review of literature. *North Clin Istanbul* 2018;5:145–7.
3. Hilfiker-Kleiner D, Haghikia A, Nonhoff J, Bauersachs J. Peripartum cardiomyopathy: Current management and future perspectives. *Eur Heart J* 2015;36:1090–7. [\[CrossRef\]](#)
4. Amos AM, Jaber WA, Russell SD. Improved outcomes in peripartum cardiomyopathy with contemporary. *Am Heart J* 2006;152:509–13.
5. Kane A, Mbaye M, Ndiaye MB, Diao M, Moreira PM, Mboup C, et al. Evolution and thromboembolic complications of the idiopathic peripartum cardiomyopathy at Dakar university hospital: Forward-looking study about 33 cases. *J Gynecol Obstet Biol Reprod (Paris)* 2010;39:484–489. [\[CrossRef\]](#)
6. Demakis JG, Rahimtoola SH. Peripartum cardiomyopathy. *Circulation* 1971;44:964–968.
7. Demakis JG, Rahimtoola SH, Sutton GC, Meadows WR, Szanto PB, Tobin JR, et al. Natural course of peripartum cardiomyopathy. *Circulation* 1971;44:1053–61. [\[CrossRef\]](#)
8. Arany Z, Elkayam U. Peripartum cardiomyopathy. *Circulation* 2016;133:1397–409. [\[CrossRef\]](#)



Received: December 25, 2018 Accepted: January 15, 2019 Online: January 20, 2019

Correspondence: Dr. Ugur AKSU. Erzurum Eğitim ve Araştırma Hastanesi, Kardiyoloji Bölümü, Erzurum, Turkey.
Tel: +90 541 787 57 25 e-mail: aksuuu001@msn.com

© Copyright 2019 by Istanbul Provincial Directorate of Health - Available online at www.northclinist.com